Newcastle Clinical Trials Unit



Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory Arthritis

Study stage: Closed
Sponsor: The Newcastle upon Tyne Hospitals NHS Foundation Trust
Funder: Arthritis Research UK
Therapeutic area: Musculoskeletal
Type of study: ATIMP

Aim: To assess safety of intra-articular TolDC in patients with RA and other chronic inflammatory arthritis

Primary Outcome:  The proportion of patients experiencing AEs and SAEs following the intra-articular administration of TolDC.

Population: Adults
Clinical Phase: I
Design: Randomised Control Trial (RCT)
Setting: Secondary Care
Planned Sample Size: 12